HRS-4357 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P3 | N=370 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P3 | N=370 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P3 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Hengrui Medicine's innovative drug HRS-4357 is approved for clinical trials for prostate cancer [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Hengrui Medicine's subsidiary Tianjin Hengrui Medicine Co., Ltd. received the 'Drug Clinical Trial Approval Notice' approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of HRS-4357 injection combined with ADT and new androgen receptor pathway inhibitors for prostate cancer."

New trial • Prostate Cancer

Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer (clinicaltrials.gov) - P1/2 | N=49 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Metastases • New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor